Denali Therapeutics, Inc. (DNLI)

24.35 +0.50 (+2.10%) USD  |  NASDAQ  |  Jul 30, 16:00
24.32 -0.03 (-0.12%) Pre-Market: 08:41
More

Denali Therapeutics EPS Diluted (Quarterly) : -0.6882 for March 31, 2026

EPS Diluted (Quarterly) Chart

View EPS Diluted (Quarterly) for DNLI.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View EPS Diluted (Quarterly) Chart
Start Trial

Historical EPS Diluted (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
March 31, 2026 -0.6882
December 31, 2025 -0.7326
September 30, 2025 -0.736
June 30, 2025 -0.7239
March 31, 2025 -0.7766
December 31, 2024 -0.6747
September 30, 2024 -0.6326
June 30, 2024 -0.5865
March 31, 2024 -0.6814
December 31, 2023 -0.8642
September 30, 2023 -0.7218
June 30, 2023 1.301
March 31, 2023 -0.8041
December 31, 2022 -0.7426
September 30, 2022 -0.8366
June 30, 2022 -0.478
March 31, 2022 -0.5316
December 31, 2021 -0.6161
September 30, 2021 -0.6948
June 30, 2021 -0.5015
Date Value
March 31, 2021 -0.5794
December 31, 2020 1.909
September 30, 2020 -0.5417
June 30, 2020 -0.5585
March 31, 2020 -0.5542
December 31, 2019 -0.5623
September 30, 2019 -0.4826
June 30, 2019 -0.6109
March 31, 2019 -0.4105
December 31, 2018 0.7932
September 30, 2018 -0.3776
June 30, 2018 -0.59
March 31, 2018 -0.2644
December 31, 2017 -0.74
September 30, 2017 -0.2425
June 30, 2017 -0.2458
March 31, 2017 1.808
December 31, 2016 -0.2149
September 30, 2016 -0.3399

EPS Diluted (Quarterly) Range, Past 5 Years

View EPS Diluted (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (Quarterly) Benchmarks

View EPS Diluted (Quarterly) Benchmarks
Start Trial
Arrowhead Pharmaceuticals, Inc. -0.932
Summit Therapeutics, Inc. -0.2772
Biogen, Inc. 0.6557
Oncolytics Biotech, Inc. -0.0823
Sangamo Therapeutics, Inc. -0.0796

EPS Diluted (Quarterly) Related Metrics

Net Income (Quarterly) -128.45M
Total Expenses (Quarterly) 128.45M
Enterprise Value 2.916B
Earnings Yield -11.83%
Normalized Earnings Yield -11.83